- Home
- IGC vs DRIO Comparison
IGC vs DRIO Comparison
Compare IGC & DRIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGC
- DRIO
- Stock Information
- Founded
- IGC 2005
- DRIO 2011
- Country
- IGC United States
- DRIO United States
- Employees
- IGC N/A
- DRIO N/A
- Industry
- IGC Biotechnology: Pharmaceutical Preparations
- DRIO Medical/Dental Instruments
- Sector
- IGC Health Care
- DRIO Health Care
- Exchange
- IGC Nasdaq
- DRIO Nasdaq
- Market Cap
- IGC 29.4M
- DRIO 27.9M
- IPO Year
- IGC N/A
- DRIO N/A
- Fundamental
- Price
- IGC $0.33
- DRIO $0.66
- Analyst Decision
- IGC Strong Buy
- DRIO Strong Buy
- Analyst Count
- IGC 2
- DRIO 1
- Target Price
- IGC $3.75
- DRIO $4.00
- AVG Volume (30 Days)
- IGC 380.9K
- DRIO 1.4M
- Earning Date
- IGC 02-12-2025
- DRIO 11-07-2024
- Dividend Yield
- IGC N/A
- DRIO N/A
- EPS Growth
- IGC N/A
- DRIO N/A
- EPS
- IGC N/A
- DRIO N/A
- Revenue
- IGC $1,183,000.00
- DRIO $23,052,000.00
- Revenue This Year
- IGC N/A
- DRIO $34.56
- Revenue Next Year
- IGC $13.38
- DRIO $39.35
- P/E Ratio
- IGC N/A
- DRIO N/A
- Revenue Growth
- IGC N/A
- DRIO N/A
- 52 Week Low
- IGC $0.27
- DRIO $0.56
- 52 Week High
- IGC $0.91
- DRIO $2.60
- Technical
- Relative Strength Index (RSI)
- IGC 41.18
- DRIO 44.57
- Support Level
- IGC $0.31
- DRIO $0.67
- Resistance Level
- IGC $0.37
- DRIO $0.78
- Average True Range (ATR)
- IGC 0.02
- DRIO 0.15
- MACD
- IGC -0.00
- DRIO -0.02
- Stochastic Oscillator
- IGC 28.17
- DRIO 11.61
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
About DRIO DarioHealth Corp.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and highly engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.